PATH Malaria Vaccine Initiative and Crucell to test new malaria vaccine approach
For MVI, this partnership adds to its existing portfolio a vaccine approach with the potential to elicit a more comprehensive immune response than has been seen to date from the circumsporozoite protein (CSP), the only antigen that has proven to be protective against malaria in controlled challenge studies and field studies. Using Crucell's AdVac technology with two different vectors — the adenovirus serotypes Ad35 and Ad26 — as delivery mechanisms, this approach seeks to elicit a protective immune response obtained from delivering the CSP. The safety, immunogenicity and efficacy data from these studies will further advance the research forward development of a safe and highly efficacious malaria vaccine.
Most read news
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.